Perry B P, Zieno S A, Yonkers A J, Moore G F
University of Nebraska Medical Center, Department of Otolaryngology-Head and Neck Surgery, Omaha 68198-1225, USA.
Ear Nose Throat J. 1995 Dec;74(12):840-4.
A study utilizing outcome-oriented cure is employed to show the effectiveness of a given medical treatment. A specific patient population is studied in order to determine the most effective treatment for a common clinical disorder. A total of 201 children were retrospectively studied to evaluate the efficacy and side effects of amoxicillin and cefaclor in the treatment of acute otitis media and recurrent acute otitis media. There were 456 episodes of acute otitis media; 245 episodes were treated with amoxicillin with an efficacy of 91%, while 211 episodes were treated with cefaclor with an efficacy of 97%. The dosage of 40 mg/kg/day, divided in three equal doses, was employed for both antibiotics in the treatment of acute otitis media, while half of this amount was given once daily for the chemoprophylaxis of recurrent acute otitis media. In the 87 courses of chemoprophylaxis with cefaclor for recurrent otitis media, the efficacy was found to be 53%; while amoxicillin was found to be effective in 30% of the 33 patients studied. There were fewer side effects noted in the cefaclor group than in the amoxicillin group (4% vs. 12%). Both drugs caused diarrhea, while cefaclor also caused a mild maculopapular rash in two patients (1.67%). While amoxicillin remains the drug of choice for acute otitis media (AOM), this study suggests that cefaclor may be a better selection in the chemoprophylaxis of recurrent acute otitis media.
一项采用以结果为导向的治疗方法的研究旨在证明某种特定药物治疗的有效性。为确定针对一种常见临床病症的最有效治疗方法,对特定患者群体进行了研究。总共对201名儿童进行了回顾性研究,以评估阿莫西林和头孢克洛治疗急性中耳炎及复发性急性中耳炎的疗效和副作用。共有456例急性中耳炎发作;245例采用阿莫西林治疗,有效率为91%,而211例采用头孢克洛治疗,有效率为97%。治疗急性中耳炎时,两种抗生素均采用每日40mg/kg的剂量,分三次等量服用,而复发性急性中耳炎的化学预防则采用该剂量的一半,每日一次。在87例采用头孢克洛进行复发性中耳炎化学预防的疗程中,发现有效率为53%;而在所研究的33例患者中,30%的患者使用阿莫西林有效。头孢克洛组的副作用比阿莫西林组少(4%对12%)。两种药物均会引起腹泻,而头孢克洛还导致两名患者出现轻度斑丘疹(1.67%)。虽然阿莫西林仍然是急性中耳炎(AOM)的首选药物,但这项研究表明,头孢克洛在复发性急性中耳炎的化学预防中可能是更好的选择。